Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not true, SDOCQ share holders were wiped out today in the bankruptcy court when the presiding judge refused to form the EC.
SDOCQ's commons sadly lost their case today, i hope breitburn's commons get some of their investment back.
Chapter 11 is approved!
This is not going in favor of commons.
Inhaling diesel fumes can damage brain cells.
This guy is a bad omen, whenever he posts a chart about any stock, the stock goes down.
UPLMQ's OS is 150 million and SDOCQ's OS is 650 million, there is no comparison between the two, based on many other reasons too.
Stop this relentless pumping!
What is the ticker symbol for the unsecured bonds of all these BK stocks?
Enough pumping!
Seems like you got stuck with Gevo, and now trying everything to get out of it, honestly I feel bad for you.
court filling says:
The Debtors have been engaged in ongoing and extensive discussions with a number of potential bidders in connection with the Sale Transaction. The Debtors have received a number of positive indications of interest and continue to work towards agreements with parties, including potential stalking horse purchasers prior to the Auction.
But some on this board is bound to lie , for personal gain.
According to your 360 law, Aero wants to push back the court date because it couldn't find a bidder?
But the court filling says:
The Debtors have been engaged in ongoing and extensive discussions with a number of potential bidders in connection with the Sale Transaction. The Debtors have received a number of positive indications of interest and continue to work towards agreements with parties, including potential stalking horse purchasers prior to the Auction.
Fair warning issued:
As more fully discussed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” in the Company’s Quarterly Report on Form 10-Q for the Quarter ended March 31, 2016, if the Company’s ongoing negotiations with its lenders and noteholders do not lead to a strategic transaction or alternative that addresses the Company’s level of indebtedness and liquidity, the Company could be forced to seek bankruptcy protection to restructure its business and capital structure. Additionally, the terms of any such transaction or the results of a bankruptcy proceeding could result in a limited recovery for unsecured noteholders, if any, and place equity holders at significant risk of losing all of their interests in our company.
Loss/share 44c
Smart!
10q is out.
I wish I bought .16's back in the day.
The biggest buyers and sellers are NITE and CDEL. They make good money by flipping GOVX, so quickly.
I saw the news on the website as breaking news and couldn't help to keep it to myself.
Breaking News
UGA and GeoVax collaborate on Zika vaccine
Breaking News
UGA and GeoVax collaborate on Zika vaccine.
Sad to say, but the reality is that bonanza will be joining other BK stocks in the near future.
Not long ago GOVX's daily average trading volume used to be less than 50k, but look at current trading volume, it's amazing.
GOVX
Vaccine to Address Four Major Hemorrhagic Fever Viruses -- Ebola, Sudan, Marburg, and Lassa; VLP Production Now Demonstrated for All Virus Targets ATLANTA, GA--(Marketwired - Jul 27, 2016) - Â Â GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today provided an update on its Tetravalent Hemorrhagic Fever Vaccine (THV) program, including a demonstration that its vaccines produce non-infectious virus-like particles (VLPs) for each of the four virus targets -- Ebola-Zaire, Ebola-Sudan, Marburg, and Lassa. GeoVax's vaccine (GOVX- E303) is based on the Company's novel Modified Vaccinia Ankara (MVA) VLP platform, which generates noninfectious VLPs. VLPs, expressed by MVA, form the base for a highly effective vaccine, because they can be engineered to display native forms of membrane-anchored viral envelope glycoproteins that mimic a natural infection. These native proteins trigger the body to produce antibody responses that are highly effective in their ability to block virus infections. Moreover, VLPs generated by GeoVax's vaccines are produced in vivo (in the very person being vaccinated) and do not have to be purified, thereby reducing manufacturing costs. GeoVax has previously demonstrated VLP formation as well as 100% protection in non-human primates after single, or prime/boost, inoculations with its Ebola-Zaire vaccine. The Zaire strain of Ebola virus was responsible for the 2014/15 outbreak in West Africa, which resulted in 28,652 infections and 11,325 deaths. The Company now has vaccine constructs against each of the three additional hemorrhagic fever targets and has demonstrated VLP production for each target infection. GeoVax's vaccines are being developed for use as either individual vaccines in epidemic or biothreat situations or combined as a single tetravalent vaccine for protection of the millions of individuals who live in at-risk areas, travelers, military personnel, and healthcare workers. Thin section electron micrographs of MVA-VLP vaccines for Zaire (EBOV), Sudan (SUDV), Marburg (MARV) and Lassa (LASV). Non-infectious VLPs budding from the surface of the cells resemble native virions. Immunogold staining was performed using antibodies specific to the glycoproteins of Zaire, Sudan and Marburg viruses (see arrows for examples of gold particles). Lassa VLPs (not immunogold stained) are 100-200 nm in diameter and contain granular structures similar in size to cellular ribosomes, 10 ~ 20 nm (large arrow points to the largest VLP in a cluster of four). Farshad Guirakhoo, Ph.D., GeoVax's Senior Vice President of Research and Development, commented, "Hemorrhagic fevers caused by filoviruses (Ebola, Sudan, and Marburg viruses) and arenaviruses, such as Lassa virus, occur in an overlapping geographical region in West Africa, putting as many as 200 million people at risk of infection with no licensed vaccines or effective therapeutics available. Lassa virus is endemic and causes severe and often fatal hemorrhagic illness with as many as 67,000 deaths per year. Although many consider MVA a boosting, not a priming, vaccine, our MVA-expressed VLPs are in fact outstanding priming vaccines. In non-human primates, we have demonstrated that a single dose of the GeoVax Ebola-Zaire vaccine elicits complete protective immunity; an important attribute for a vaccine which can be used for travelers or to stem an ongoing epidemic/endemic situation."Â Robert McNally, Ph.D., GeoVax's President and CEO, said, "The lessons learned from the 2014/15 Ebola outbreak indicate that the urbanization of Africa contributes to the rapid spread of emergent viruses. If not contained, they can cause global epidemics. The commercial opportunity for our HFV vaccine program is very attractive, particularly for Lassa fever, given the endemic nature of the virus. Currently, ribavirin is used for Lassa fever treatment, but it seems to be effective only if given early on in the course of clinical illness. These viruses could also be intentionally used as biological warfare agents, which makes vaccine development against these agents of high interest to the U.S. Department of Defense and related agencies." About GeoVax GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. The Company's development programs are focused on vaccines against HIV, Zika Virus, and hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa). GeoVax also recently began programs to evaluate the use of its MVA-VLP platform in cancer immunotherapy, and for therapeutic use in chronic Hepatitis B infections. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the very person receiving the vaccine, mimicking a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. For more information, visit www.geovax.com. Forward-Looking Statements Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent targeted infections in humans, GeoVax's vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K. Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=3037790 GeoVax Labs, Inc. Robert T. McNally, Ph.D. investor@geovax.com 678-384-7220
With such substantial amount of $7.6 million GOVX dose not need to sell its stocks anymore because it will worth much more in near term.
GOVX is awarded $7.8 million contract.
The base portion of the contract, with a value of $199,442, will support preparatory work for initiation of manufacturing. The contract also includes $7.6 million in additional development options that may be exercised by NIAID, bringing the total potential value of the contract to $7.8 million. The multi-year contract will pay 100% of the manufacturing cost of the DNA vaccine component of GeoVax's HIV vaccine candidate, GOVX-B11.
The base portion of the contract, with a value of $199,442, will support preparatory work for initiation of manufacturing. The contract also includes $7.6 million in additional development options that may be exercised by NIAID, bringing the total potential value of the contract to $7.8 million. The multi-year contract will pay 100% of the manufacturing cost of the DNA vaccine component of GeoVax's HIV vaccine candidate, GOVX-B11.
I'm out, good luck to all share holders.
Key energy services, KEGX is on OTC now.
I am not sure if I am understanding what I am reading below?
The Certificate of Incorporation provides that the Company is authorized to issue 100,000,000 shares of capital stock, divided into two classes consisting of (a) 90,000,000 shares of common stock, par value $0.01 per share and (b) 10,000,000 shares of preferred stock, par value $0.01 per share.
I meant 20% of 0.01 would be 0.0020?
So 20% of 0.01 is 0.0080?
I am not sure if I am understanding what I am reading below?
The Certificate of Incorporation provides that the Company is authorized to issue 100,000,000 shares of capital stock, divided into two classes consisting of (a) 90,000,000 shares of common stock, par value $0.01 per share and (b) 10,000,000 shares of preferred stock, par value $0.01 per share.
The Debtors plan to emerge from Chapter 11 on or about August 1, 2016 (the “Effective Date”), Upon the Effective Date, as previously disclosed, all of the Company’s existing common stock will be cancelled and the reorganized Company will issue to such stockholders two series of warrants exercisable for an aggregate of 20% of the new common stock at predetermined equity values.
Key is contemplating chapter 11. The announcement can come soon.
KEGX, will wipe out all the commons.
BK is imminent.
RIP, Atlas Resource Partners
http://www.seekingalpha.com/article/3991382